Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)
The rise in the incidence of nonalcoholic steatohepatitis (NASH) has necessitated the development of an effective prevention methodology. An antidiabetic drug, belonging to the group of sodium glucose cotransporter 2 (SGLT2) inhibitors, has been tested for its therapeutic effect on NASH; however, no...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-04-01
|
| Series: | FEBS Open Bio |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/2211-5463.12598 |
| _version_ | 1827942573453344768 |
|---|---|
| author | Ryo Goto Kenya Kamimura Yoko Shinagawa‐Kobayashi Norihiro Sakai Takuro Nagoya Yusuke Niwa Masayoshi Ko Kohei Ogawa Ryosuke Inoue Takeshi Yokoo Akira Sakamaki Hiroteru Kamimura Satoshi Abe Hiroshi Nishina Shuji Terai |
| author_facet | Ryo Goto Kenya Kamimura Yoko Shinagawa‐Kobayashi Norihiro Sakai Takuro Nagoya Yusuke Niwa Masayoshi Ko Kohei Ogawa Ryosuke Inoue Takeshi Yokoo Akira Sakamaki Hiroteru Kamimura Satoshi Abe Hiroshi Nishina Shuji Terai |
| author_sort | Ryo Goto |
| collection | DOAJ |
| description | The rise in the incidence of nonalcoholic steatohepatitis (NASH) has necessitated the development of an effective prevention methodology. An antidiabetic drug, belonging to the group of sodium glucose cotransporter 2 (SGLT2) inhibitors, has been tested for its therapeutic effect on NASH; however, no studies to date have demonstrated the preventive effect of an SGLT2 inhibitor on the histological progression of steatosis and fibrosis in a sequential manner in animal models. In the present study, we examined the effect of the SGLT2 inhibitor, tofogliflozin (Tofo), on NASH liver tissue using medaka as an animal model, maintaining a feeding amount and drug concentration in all animal bodies. We generated a medaka NASH model by feeding d‐rR/Tokyo medaka a high‐fat diet and administered Tofo by dissolving the drug directly in the water of the feeding tank. Thereafter, the effects of Tofo on body weight (BW), liver weight, hepatotoxicity, fatty infiltration, and fibrotic changes in the liver were examined. We report here that SGLT2 is expressed in medaka fish and that Tofo inhibits the accumulation of fatty tissue and delays the progression of liver fibrosis in the medaka NASH model by inhibiting increases in blood sugar, serum lipids, and transaminase, irrespective of changes in BW. These results suggest that Tofo is effective for treating NASH and that the medaka model may be useful for developing new therapeutic drugs for this disease. |
| first_indexed | 2024-03-13T10:00:14Z |
| format | Article |
| id | doaj.art-e3afa94b88344eed9fd838e18dbfc43a |
| institution | Directory Open Access Journal |
| issn | 2211-5463 |
| language | English |
| last_indexed | 2024-03-13T10:00:14Z |
| publishDate | 2019-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | FEBS Open Bio |
| spelling | doaj.art-e3afa94b88344eed9fd838e18dbfc43a2023-05-23T06:46:21ZengWileyFEBS Open Bio2211-54632019-04-019464365210.1002/2211-5463.12598Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)Ryo Goto0Kenya Kamimura1Yoko Shinagawa‐Kobayashi2Norihiro Sakai3Takuro Nagoya4Yusuke Niwa5Masayoshi Ko6Kohei Ogawa7Ryosuke Inoue8Takeshi Yokoo9Akira Sakamaki10Hiroteru Kamimura11Satoshi Abe12Hiroshi Nishina13Shuji Terai14Division of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University JapanDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University JapanDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University JapanDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University JapanDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University JapanDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University JapanDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University JapanDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University JapanDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University JapanDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University JapanDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University JapanDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University JapanDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University JapanDepartment of Developmental and Regenerative Biology Medical Research Institute Tokyo Medical and Dental University JapanDivision of Gastroenterology and Hepatology Graduate School of Medical and Dental Sciences Niigata University JapanThe rise in the incidence of nonalcoholic steatohepatitis (NASH) has necessitated the development of an effective prevention methodology. An antidiabetic drug, belonging to the group of sodium glucose cotransporter 2 (SGLT2) inhibitors, has been tested for its therapeutic effect on NASH; however, no studies to date have demonstrated the preventive effect of an SGLT2 inhibitor on the histological progression of steatosis and fibrosis in a sequential manner in animal models. In the present study, we examined the effect of the SGLT2 inhibitor, tofogliflozin (Tofo), on NASH liver tissue using medaka as an animal model, maintaining a feeding amount and drug concentration in all animal bodies. We generated a medaka NASH model by feeding d‐rR/Tokyo medaka a high‐fat diet and administered Tofo by dissolving the drug directly in the water of the feeding tank. Thereafter, the effects of Tofo on body weight (BW), liver weight, hepatotoxicity, fatty infiltration, and fibrotic changes in the liver were examined. We report here that SGLT2 is expressed in medaka fish and that Tofo inhibits the accumulation of fatty tissue and delays the progression of liver fibrosis in the medaka NASH model by inhibiting increases in blood sugar, serum lipids, and transaminase, irrespective of changes in BW. These results suggest that Tofo is effective for treating NASH and that the medaka model may be useful for developing new therapeutic drugs for this disease.https://doi.org/10.1002/2211-5463.12598d‐rR/Tokyo medakaliver fibrosisNASHSGLT2tofogliflozin |
| spellingShingle | Ryo Goto Kenya Kamimura Yoko Shinagawa‐Kobayashi Norihiro Sakai Takuro Nagoya Yusuke Niwa Masayoshi Ko Kohei Ogawa Ryosuke Inoue Takeshi Yokoo Akira Sakamaki Hiroteru Kamimura Satoshi Abe Hiroshi Nishina Shuji Terai Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH) FEBS Open Bio d‐rR/Tokyo medaka liver fibrosis NASH SGLT2 tofogliflozin |
| title | Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH) |
| title_full | Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH) |
| title_fullStr | Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH) |
| title_full_unstemmed | Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH) |
| title_short | Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH) |
| title_sort | inhibition of sodium glucose cotransporter 2 sglt2 delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis nash |
| topic | d‐rR/Tokyo medaka liver fibrosis NASH SGLT2 tofogliflozin |
| url | https://doi.org/10.1002/2211-5463.12598 |
| work_keys_str_mv | AT ryogoto inhibitionofsodiumglucosecotransporter2sglt2delaysliverfibrosisinamedakamodelofnonalcoholicsteatohepatitisnash AT kenyakamimura inhibitionofsodiumglucosecotransporter2sglt2delaysliverfibrosisinamedakamodelofnonalcoholicsteatohepatitisnash AT yokoshinagawakobayashi inhibitionofsodiumglucosecotransporter2sglt2delaysliverfibrosisinamedakamodelofnonalcoholicsteatohepatitisnash AT norihirosakai inhibitionofsodiumglucosecotransporter2sglt2delaysliverfibrosisinamedakamodelofnonalcoholicsteatohepatitisnash AT takuronagoya inhibitionofsodiumglucosecotransporter2sglt2delaysliverfibrosisinamedakamodelofnonalcoholicsteatohepatitisnash AT yusukeniwa inhibitionofsodiumglucosecotransporter2sglt2delaysliverfibrosisinamedakamodelofnonalcoholicsteatohepatitisnash AT masayoshiko inhibitionofsodiumglucosecotransporter2sglt2delaysliverfibrosisinamedakamodelofnonalcoholicsteatohepatitisnash AT koheiogawa inhibitionofsodiumglucosecotransporter2sglt2delaysliverfibrosisinamedakamodelofnonalcoholicsteatohepatitisnash AT ryosukeinoue inhibitionofsodiumglucosecotransporter2sglt2delaysliverfibrosisinamedakamodelofnonalcoholicsteatohepatitisnash AT takeshiyokoo inhibitionofsodiumglucosecotransporter2sglt2delaysliverfibrosisinamedakamodelofnonalcoholicsteatohepatitisnash AT akirasakamaki inhibitionofsodiumglucosecotransporter2sglt2delaysliverfibrosisinamedakamodelofnonalcoholicsteatohepatitisnash AT hiroterukamimura inhibitionofsodiumglucosecotransporter2sglt2delaysliverfibrosisinamedakamodelofnonalcoholicsteatohepatitisnash AT satoshiabe inhibitionofsodiumglucosecotransporter2sglt2delaysliverfibrosisinamedakamodelofnonalcoholicsteatohepatitisnash AT hiroshinishina inhibitionofsodiumglucosecotransporter2sglt2delaysliverfibrosisinamedakamodelofnonalcoholicsteatohepatitisnash AT shujiterai inhibitionofsodiumglucosecotransporter2sglt2delaysliverfibrosisinamedakamodelofnonalcoholicsteatohepatitisnash |